Search Results
Dr. Matulonis on Toxicities With PARP Inhibitors in Ovarian Cancer
Toxicities Associated with PARP Inhibitors in Ovarian Cancer
Dr. Matulonis on Toxicities With Olaparib for Patients With Ovarian Cancer
Dr. Matulonis on the Current Treatment Landscape in Ovarian Cancer
Expert Perspectives: The Clinical Potential of PARP Inhibitors in Ovarian Cancer
Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian Cancer
Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer
Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer
PARP Inhibitors: New Insights & Future of Ovarian Cancer Treatment
Stanford Cancer Institute Breakthroughs in Cancer: Ursula Matulonis, MD
Difference Among PARP Inhibitors for Ovarian Cancer
OvarInform: Knowledge Series featuring The Advances And Future Scenarios in PARP Inhibitors
